European Trial Into Mpox Infection

Exclusion Criteria11

• Age <18 years.
• Body weight <40 kg
• Pregnant and breastfeeding patients are not eligible for inclusion in this study.
• Lack of mental capacity to provide informed consent
• Trial participation is considered not in the best interest of patient
• Known hypersensitivity to the active substance or to any of the excipients of the study drug.
• Use of contraindicated treatment repaglinide. (Repaglinide, an oral treatment for diabetes mellitus, may be discontinued while taking study treatment with the agreement of the patient's general practitioner, who may start alternate diabetes treatment if considered necessary.)
• Previous, current or planned use of another investigational drug (tecovirimat) at any point during study participation.
• The patient's own doctor considers there to be a definite indication for the patient to receive tecovirimat or the local guidelines establish that tecovirimat treatment should be initiated
• The patient's own doctor considers there to be a definite contraindication to the patient receiving tecovirimat.
• The patient suffers from hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.